Characterization of the metabolic changes underlying growth factor angiogenic activation: Identification of new potential therapeutic targets

Carcinogenesis

Volumn 30, Issue 6, 2009, Pages 946-952

  Vizán, Pedro ^d   Sánchez Tena, Susana ^a   Alcarraz Vizán, Gema ^a   Soler, Marta ^e   Messeguer, Ramon ^b   Pujol, M Dolors ^a   Lee, Wai Nang Paul ^c   Cascante, Marta ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b LEITAT TECHNOLOGICAL CENTER   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CP 320626; FIBROBLAST GROWTH FACTOR; LACTIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HUMAN; HUMAN CELL; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR VASCULARIZATION; UMBILICAL VEIN;

AMIDES; CARBON ISOTOPES; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTORS; GLUCOSE; GLUCOSEPHOSPHATE DEHYDROGENASE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; HUMANS; INDOLES; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PENTOSE PHOSPHATE PATHWAY; PYRANS; SULFHYDRYL COMPOUNDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 66749132763     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp083     Document Type: Article

References (50)

1. Ferrara,N. (1999) Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med., 77, 527-543.
2. Ferrara,N. (2002) VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer, 2, 795-803.
3. Brekken,R.A. et al. (2000) Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res., 60, 5117-5124.
4. Ferrara,N. et al. (2005) Angiogenesis as a therapeutic target. Nature, 438, 967-974.
5. Ferrara,N. (2005) VEGF as a therapeutic target in cancer. Oncology 69 (suppl. 3), 11-16.
6. Kerbel,R. et al. (2002) Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2, 727-739.
7. Kell,D.B. et al. (2005) Metabolic footprinting and systems biology: The medium is the message. Nat. Rev. Microbiol., 3, 557-565.
8. Boros,L.G. et al. (2002) Metabolic profiling of cell growth and death in cancer: Applications in drug discovery. Drug Discov. Today 7, 364-372.
9. Nicholson,J.K. et al. (2002) Metabonomics: A platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov., 1, 153-161.
10. Dagher,Z. et al. (1999) The effect of AMP-activated protein kinase and its activator AICAR on the metabolism of human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun., 265, 112-115.
11. Ido,Y. et al. (2002) Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: Inhibition by the AMP-activated protein kinase activation. Diabetes, 51, 159-167.
12. Mori,N. et al. (2003) Choline phospholipid metabolites of human vascular endothelial cells altered by cyclooxygenase inhibition, growth factor depletion, and paracrine factors secreted by cancer cells. Mol. Imaging, 2, 124-130.
13. Gatenby,R.A. et al. (2003) The glycolytic phenotype in carcinogenesis and tumor invasion: Insights through mathematical models. Cancer Res., 63, 3847-3854.
14. Dang,C.V. et al. (1999) Oncogenic alterations of metabolism. Trends Biochem. Sci., 24, 68-72.
15. Mazurek,S. et al. (2003) The tumor metabolome. Anticancer Res. 23, 1149-1154.
16. Vizán,P. et al. (2008) Robust metabolic adaptation underlying tumor progression. Metabolomics, 4, 1-12.
17. Purcell,W.T. et al. (2003) Novel antifolate drugs. Curr. Oncol. Rep., 5, 114-125.
18. Boren,J. et al. (2002) Metabolic control analysis aimed at the ribose synthesis pathways of tumor cells: A new strategy for antitumor drug development. Mol. Biol. Rep., 29, 7-12.
19. Boros,L.G. et al. (1997) Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res., 57, 4242-4248.
20. Cascante,M. et al. (2002) Metabolic control analysis in drug discovery and disease. Nat. Biotechnol., 20, 243-249.
21. Comin-Anduix,B. et al. (2001) The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur. J. Biochem., 268, 4177-4182.
22. Rais,B. et al. (1999) Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett., 456, 113-118.
23. Pelicano,H. et al. (2006) Glycolysis inhibition for anticancer treatment. Oncogene, 25, 4633-4646.
24. Gatenby,R.A. et al. (2007) Glycolysis in cancer: A potential target for therapy. Int. J. Biochem. Cell Biol., 39, 1358-1366.
25. Xu,R.H. et al. (2005) Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res., 65, 613-621.
26. Boren,J. et al. (2003) The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J. Biol. Chem. 278, 28395-28402.
27. Vizan,P. et al. (2005) K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res., 65, 5512-5515.
28. Miyazaki,Y. et al. (2007) Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2. Bioorg. Med. Chem. Lett., 17, 1773-1778.
29. Kunst,A. et al. (1984) D-Glucose: UV-methods with hexokinase and glucose-6-phosphate dehydrogenase. In: Bergmeyer,H.U. (ed.), Methods of Enzymatic Analysis, Vol. VI, Verlag Chemie, Weinheim, Germany, pp. 163-172.
30. Passoneau,J.V. et al. (1974) L-(+)-lactate: Fluorometric method. In: Bergmeyer,H.U. (ed.), Methods of Enzymatic Analysis, Vol. III, Academic press, New york, pp. 1468-1472.
31. Lee,W.N. et al. (1998) Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. Am. J. Physiol. 274, E843-E851.
32. Boros,L.G. et al. (2001) Wheat germ extract decreases glucose uptake and RNA ribose formation but increases fatty acid synthesis in MIA pancreatic adenocarcinoma cells. Pancreas, 23, 141-147.
33. Szafranek,J. et al. (1974) The mass spectra of some per-O-acetylaldononitriles. Carbohydr. Res., 38, 97-105.
34. Lerin,C. et al. (2004) Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. Biochem. J., 378, 1073-1077.
35. Mosmann,T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
36. Matito,C. et al. (2003) Antiproliferative effect of antioxidant polyphenols from grape in murine Hepa-1c1c7. Eur. J. Nutr., 42 43-49.
37. Deng,Q. et al. (2005) Modeling aided design of potent glycogen phosphorylase inhibitors. J. Mol. Graph. Model., 23, 457-464.
38. Hoover,D.J. et al. (1998) Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J. Med. Chem., 41, 2934-2938.
39. Keely,P.J. et al. (1997) Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature, 390, 632-636.
40. Artwohl,M. et al. (2007) Insulin does not regulate glucose transport and metabolism in human endothelium. Eur. J. Clin. Invest. 37, 643-650.
41. Vizan,P. et al. (2007) Quantification of intracellular phosphorylated carbohydrates in HT29 human colon adenocarcinoma cell line using liquid chromatography-electrospray ionization tandem mass spectrometry. Anal. Chem., 79, 5000-5005.
42. Lee,W.N. et al. (2004) Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. Br. J. Cancer, 91, 2094-2100.
43. Ramos-Montoya,A. et al. (2006) Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. Int. J. Cancer, 119, 2733-2741.
44. Frederiks,W.M. et al. (2008) Elevated activity of the oxidative and nonoxidative pentose phosphate pathway in (pre)neoplastic lesions in rat liver. Int. J. Exp. Pathol., 89, 232-240.
45. Oikonomakos,N.G. et al. (2000) A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure, 8 575-584.
46. Kitano,H. (2004) Cancer as a robust system: Implications for anticancer therapy. Nat. Rev. Cancer, 4, 227-235.
47. de la Fuente,A. et al. (2002) Metabolic control in integrated biochemical systems. Eur. J. Biochem., 269, 4399-4408.
48. Boros,L.G. et al. (1998) Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: A possible mechanism of antitumor action. Med. Hypotheses, 50, 501-506.
49. Leopold,J.A. et al. (2003) Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J. Biol. Chem., 278, 32100-32106.
50. Ascher,E. et al. (2001) Thiamine reverses hyperglycemia-induced dysfunction in cultured endothelial cells. Surgery, 130, 851-858.